• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Kazakhstan Pharmaceuticals and Healthcare Report Q1 2009 - Product Image

Kazakhstan Pharmaceuticals and Healthcare Report Q1 2009

  • Published: February 2009
  • Region: Kazakhstan
  • 68 Pages
  • Business Monitor International

FEATURED COMPANIES

  • Chimpharm
  • GlaxoSmithKline (GSK)
  • Merck & Co
  • Novartis (Sandoz)
  • Nycomed
  • Pfizer
  • MORE

Kazakhstan Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Kazakhstan's pharmaceuticals and healthcare industry.

Kazakhstan’s pharmaceutical market remains one of the least developed among BMI’s Emerging Europe region. In our Business Environment Rankings for Q109, the country places joint 13th with Bulgaria. While the market remains dynamic, relatively low absolute and per capita spending remain key drawbacks for pharmaceutical companies. In addition, regulation governing the sector remains basic and access to healthcare poor.

Nevertheless, prospects for the market appear strong over the next five years. BMI has extended its forecasts through to 2013 for the Q109 report and our projections suggest that per capita pharmaceutical expenditure is expected to reach a value of US$140 by that year – more than double its current level. Furthermore, as regulation of the sector develops over the coming years, all sectors are likely to reap the benefits.

Efforts to provide universal healthcare will improve access to prescription medicines, while the search for value will also drive sales for over-the-counter READ MORE >

- Executive Summary
- Kazakhstan Pharmaceuticals And Healthcare SWOT
- Kazakhstan Political SWOT
- Kazakhstan Political SWOT
- Kazakhstan Economic SWOT
- Kazakhstan – Business Environment Ranking
- Table: Central And Eastern Europe Pharmaceutical And Healthcare Business Environment Rankings
- Limits Of Potential Returns
- Risks To Realisation Of Returns
- Kazakhstan – Market Summary
- Regulatory Regime
- Intellectual Property Environment
- Counterfeit Drugs
- Pricing And Reimbursement Regime
- Table: Price Components And Add-Ons For Imported And Locally Produced Generic Medicines (KZT)
- Recent Pricing And Reimbursement Developments
- Industry Developments
- Epidemiology
- Healthcare Sector
- Table: Top 10 Manufacturers By Value Of Hospital Purchases
- Table: Top 10 INNs By Value Of Hospital Purchases
- Healthcare Sector Financing
- Table: Top 10 ATC Groups By Value Of Hospital Purchases
- Table: Top 10 ATC Groups By Retail Pharmacy Sales
- Domestic Pharmaceutical Industry
- Recent Domestic Industry Developments
- Wholesale And Retail
- Recent Wholesale And Retail Developments Foreign Pharmaceutical Industry
- Table: Indo-Kazakh Trade Figures, 1999-2003 (US$mn)
- Recent Foreign Industry Developments
- Table: Pharmaniaga’s Key Products
- Clinical Trials
- Medical Devices
- Table Medical Devices Market In Kazakhstan, 2003-2005 (US$mn)
- Industry Forecast Scenario
- Overall Market Forecast
- Table: Kazakhstan’s Drug Expenditure Indicators, 2004-2013
- Key Growth Factors – Industry
- Table: Kazakhstan’s Health Expenditure Indicators, 2004-2013
- Key Growth Factors – Macroeconomic
- Table: Kazakhstan – Economic Activity
- Prescription Market Forecast
- Table: Kazakhstan’s Prescription Market Indicators, 2004-2013 (KZTmn unless otherwise stated)
- OTC Market Forecast
- Table: Kazakhstan’s OTC Market Indicators, 2004-2013 (KZTmn unless otherwise stated)
- Patented Market Forecast
- Table: Kazakhstan’s Patented Drug Market Indicators, 2004-2013
- Generics Market Forecast
- Table: Kazakhstan’s Generics Market Indicators, 2004-2013 (KZTmn unless otherwise stated)
- Export/Import Market Forecasts
- Table: Kazakhstan’s Pharmaceutical Trade Indicators, 2004-2013 (US$mn unless otherwise stated) Table Retail Sales Structure Of Imports By Pharmaceutical Subgroups, 2006
- Table: Top 15 Distributors By Value Importing Pharmaceuticals Into Kazakhstan, 2006
- Table: Top 15 Distributors By Volume Importing Pharmaceuticals Into Kazakhstan, 2006
- Other Healthcare Data Forecasts
- Table: Kazakhstan’s Other Healthcare Data, 2004-2013
- Key Risks To BMI’s Forecast Scenario
- Competitive Landscape
- Table: Top 10 Manufacturers By Retail Pharmacy Sales
- Table: Top 10 Trade Names By Value Of Retail Pharmacy Sales
- Company Monitor
- Foreign Companies
- Novartis (Sandoz)
- Sanofi-Aventis
- GlaxoSmithKline (GSK)
- Nycomed
- Merck & Co
- Pfizer
- Ranbaxy
- Indigenous Companies
- Chimpharm
- Romat FK
- Country Snapshot: Kazakhstan Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 1999-2004
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
- BMI Forecast Modelling
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources

- Novartis (Sandoz)
- Sanofi-Aventis
- GlaxoSmithKline (GSK)
- Nycomed
- Merck & Co
- Pfizer
- Ranbaxy
- Chimpharm
- Romat FK

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos